• LY294002: Designing Better PI3K Experiments

  2026-09-24

  LY294002 can help translational researchers interrogate PI3K signaling—but meaningful conclusions depend on context, orthogonal readouts, and careful attention to its broader target profile. This article connects pathway biology with practical experimental design and clarifies what a microglial P2Y2 study can, and cannot, tell us about PI3K research.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-09-24

  Use Anlotinib hydrochloride to connect inhibition of VEGFR2, PDGFRβ, and FGFR1 with measurable endothelial migration and tube-formation outcomes. This workflow-focused guide explains how to select starting conditions, separate signaling effects from cytotoxicity, and troubleshoot variable angiogenesis assays.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-09-23

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based assays, including in situ hybridization and Northern blotting. It is intended for research use only; it is not validated for diagnostic, therapeutic, or clinical use.

• Cytosine Base Editing: Fidelity Before Translation

  2026-09-23

  Cytosine base editing can install precise point mutations without double-strand DNA breaks, but translational confidence depends on more than editing rate. This article connects whole-genome evidence, mRNA workflow design, product selection, and decision gates for responsible research use of EZ Cap™ CBEmax mRNA (m1Ψ).

• Grazoprevir/Elbasvir Therapy for HCV: Evidence Review

  2026-09-22

  The reference review explains how complementary NS3/4A and NS5A inhibition established an interferon-free, fixed-dose strategy for chronic hepatitis C. Its synthesis highlights high sustained virologic response rates, activity across important patient subgroups, and the need to interpret genotype, resistance, comorbidity, and drug-interaction data together.

• Nilotinib in Alzheimer’s Disease: What the 2024 Study Shows

  2026-09-22

  The 2024 Life study tested whether Nilotinib could alter amyloid-processing and mitochondrial-health markers in SH-SY5Y human neuroblastoma cells. Although the treatment changed selected protein levels, it did not produce a consistent neuroprotective expression profile, so the findings do not support efficacy for Alzheimer’s disease without further validation.

• PD 0332991: Separating Arrest from Cell Death

  2026-09-21

  PD 0332991 and Palbociclib HCl are powerful tools for studying CDK4/6-driven cell-cycle control. This guide explains how to distinguish cytostatic G1 arrest from genuine cell killing when designing cancer assays.

• Dasatinib (BMS-354825): Assay Reliability Guide

  2026-09-21

  This scenario-driven guide shows how Dasatinib (BMS-354825), SKU A3017, can help researchers separate kinase-pathway inhibition from direct cytotoxicity, optimize DMSO-based workflows, and interpret cell and animal data responsibly. It also provides practical criteria for selecting a well-documented research-use kinase inhibitor.

• Crizotinib Hydrochloride in ALK Research

  2026-09-20

  Crizotinib hydrochloride is an ATP-competitive ALK kinase inhibitor that also targets c-Met and ROS1. Its defined kinase mechanism makes it useful for cancer biology research, while patient-derived assembloid studies show why stromal context must be measured when interpreting drug response.

• NADH Redox Mapping: From Coenzyme to Assay

  2026-09-19

  NADH is more than an electron donor: its ratio with NAD⁺ can reveal how cells allocate metabolic and respiratory capacity. This guide translates redox biology into practical assay decisions, disease-model applications, and evidence-based handling of research-grade reduced nicotinamide adenine dinucleotide.

• Elbasvir–Grazoprevir in Hepatitis C

  2026-09-18

  The reference review evaluates elbasvir–grazoprevir as a dual direct-acting antiviral regimen, integrating NS5A and NS3/4A inhibition with pharmacokinetic, efficacy, resistance, and safety evidence. Its main practical conclusion is that the fixed-dose combination is particularly well supported for HCV genotypes 1 and 4, including selected patients with cirrhosis, HIV/HCV coinfection, or advanced renal impairment.

• (5Z)-7-Oxozeaenol: TAK1 and Stress Signaling

  2026-09-18

  A translational framework for using (5Z)-7-Oxozeaenol to separate TAK1-dependent inflammatory signaling from AMPK–SQSTM1 metabolic adaptation, with practical guidance for mechanism-focused studies.

• Jiedu Xiaozheng Yin in Colitis-Associated Colorectal Cancer

  2026-09-17

  The reference study shows that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer progression by shifting intestinal macrophages toward an M1-like phenotype through TLR4-linked signaling. Its integrated mouse and RAW264.7-cell experiments connect reduced tumor burden with changes in inflammatory markers, phagocytosis, and M1/M2 polarization, while pharmacologic pathway perturbation provides mechanistic support.

• Bay 11-7085: NF-κB Workflow Guide

  2026-09-17

  Bay 11-7085 provides a practical chemical route for testing how NF-κB signaling connects inflammatory stimulation with cell-cycle arrest and apoptosis. This guide translates its mechanism into reproducible cell assays, endometriosis and meningitis applications, and an ER-stress-informed neuroinflammation workflow.

• Tin Mesoporphyrin IX: A Causal HO-1 Probe

  2026-09-16

  Tin Mesoporphyrin IX (chloride) enables causal interrogation of heme oxygenase signaling rather than simple pathway correlation. This article connects its biochemical selectivity with HO-1/ROS findings in hepatitis B research and outlines assay decisions for metabolic disease research.

8159 records 1/544 page Next 12345 下5页 Last page